Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 10,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total transaction of $5,504,562.00.

United Therapeutics Trading Down 0.1 %

Shares of NASDAQ:UTHR traded down $0.33 on Wednesday, reaching $376.67. 152,217 shares of the company traded hands, compared to its average volume of 457,030. The stock has a market capitalization of $16.82 billion, a P/E ratio of 16.34, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The business's 50-day simple moving average is $366.18 and its 200 day simple moving average is $333.84.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. During the same period in the prior year, the firm earned $5.38 EPS. The company's revenue was up 22.9% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on UTHR shares. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Bank of America decreased their price objective on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a report on Thursday, August 1st. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $370.86.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. ClariVest Asset Management LLC grew its position in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $30,000. Innealta Capital LLC bought a new position in United Therapeutics in the 2nd quarter valued at $33,000. USA Financial Formulas purchased a new stake in United Therapeutics in the third quarter worth $33,000. Finally, Brooklyn Investment Group purchased a new stake in shares of United Therapeutics during the third quarter valued at $33,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.